Table 1.
Characteristics of older patients undergoing postremission therapy for AML (N = 40)
| Characteristics | Median (25th, 75th percentiles) or % |
|---|---|
| Demographics | |
| Age, y | 68.7 (66.0, 75.5) |
| 60-69 | 57.5 |
| 70-79 | 32.5 |
| ≥80 | 10.0 |
| Sex (male) | 57.5 |
| Race (white) | 95.0 |
| Education level* | |
| Less than high school | 18.0 |
| High school | 25.6 |
| College/above | 56.4 |
| Clinical | |
| Hemoglobin, g/dL | 10.9 (10.3, 12.2) |
| Lactate dehydrogenase, U/L | 186.5 (171.0, 215.5) |
| White blood cell count, ×103/μL | 6.7 (4.8, 9.0) |
| Creatinine, mg/dL | 0.9 (0.8, 1.1) |
| Body mass index, kg/m2 | 25.4 (22.8, 28.8) |
| ECOG score (≤1)† | 68.4 |
| Prior myelodysplastic syndrome | 15.0 |
| Cytogenetic risk group* | |
| Favorable | 5.1 |
| Intermediate | 71.8 |
| Poor | 23.1 |
| Coronary artery disease | 15.0 |
| Chronic obstructive pulmonary disease | 12.5 |
| Diabetes mellitus | 22.5 |
| Congestive heart failure | 7.5 |
| Antidepressant use at diagnosis | 17.5 |
| Induction treatment | |
| Anthracycline+cytarabine | 52.5 |
| Anthracycline+cytarabine+etoposide | 20.0 |
| Other | 27.5 |
| Received 1 cycle of induction therapy vs >1 | 60 |
| Postremission therapy | |
| Initial therapy | |
| Cytarabine | 77.5 |
| Hypomethylating agent | 10 |
| Other (cytarabine+bortezomib, n = 1; cyclophosphamide+etoposide, n = 3; cytarabine+mitoxantrone, n = 1) | 12.5 |
| Dose of cytarabine consolidation, g/m2 | |
| 0.5 | 7.5 |
| 1.0 | 17.5 |
| 1.5 | 37.5 |
| 2.0 | 27.5 |
| Received peripheral blood stem cell transplantation | 22.5 |
| Geriatric assessment scores | |
| Cognition | |
| Modified Mini-Mental State Exam‡ (range 0-100, impairment <77) | 88.0 (81.0, 92.0); 20.0% impaired |
| Psychological function | |
| Center for Epidemiologic Studies Depression Scale (range 0-60, impairment ≥16)* | 8.0 (3.0, 18.0); 25.6% impaired |
| Distress Thermometer (range 0-10, impairment ≥4)* | 3.0 (0.0, 5.0); 35.9% impaired |
| Comorbidity | |
| HCT-CI (impairment >2) | 2.0 (1.0, 4.0); 40.0% impaired |
| No. of prescription medications | 8.0 (5.0-10.5); 70.0% impaired |
| Physical function§ | |
| ADL subscale | 1.3 (1.0, 1.6); 65.0% impaired |
| Instrumental ADL subscale¶ | 1.8 (1.2, 2.8); 60.0% impaired |
| Mobility subscale|| | 2.7 (1.8, 4.3); 82.5% impaired |
| SPPB (range 0-12, impairment <9) | 6.0 (0.0, 9.0); 70.0% impaired |
| Grip strength, kg | |
| Male (impairment <26) | 36.0 (22.0, 45.0); 21.7% impaired |
| Female (impairment <16) | 20.0 (18.0, 26.0); 0% impaired |
For Modified Mini-Mental State Exam, SPPB, and grip strength, a higher score reflects better function. For Center for Epidemiologic Studies Depression, Distress Thermometer, ADL, Instrumental ADL, Mobility, and HCT-CI, a higher score reflects worse function.
*
One subject had missing data.
†
Two subjects had missing data.
‡
Three subjects had missing data.
§
Results based on subjects with calculable survey scores.
¶
Twelve subjects had missing data.
||
Ten subjects had missing data.